TABLE 3.
Complementation of CHO mutants and patient fibroblasts by RnPEX12a
| CHO mutant | No. of peroxisome-positive clones | Patient fibroblasts from complementation group(s) | Peroxisome positiveb |
|---|---|---|---|
| A, VIII | − | ||
| B, VII | − | ||
| ZP92 | 0 | C, IV | − |
| D, IX | − | ||
| Z24 | 0 | E, I | − |
| Z65 | 0 | F, X | − |
| ZP105 | 0 | II | − |
| ZP104 | 24 | III | + |
| ZP109 | 20 | III | + |
| VI | − | ||
| G | − |
Peroxisome-deficient CHO mutants of five CGs were transfected with pUcD2Hyg · RnPEX12, and stable transformants were selected with hygromycin B for 5 days. Transfectants were stained with anti-rat catalase antibody. Peroxisome-positive colonies among 30 hygromycin-resistant colonies were counted on day 6 posttransfection. Patient fibroblasts of 10 CGs of peroxisomal diseases, i.e., CGs A, B, C, D, E, F, and G of Gifu University, Gifu, Japan, and CGs II, III (patients PBD3-01 and PBD3-03), and VI of the Kennedy-Krieger Institute, Baltimore, Md., were transfected with pUcD2Hyg · RnPEX12 and examined for peroxisome assembly by immunostaining with anti-human catalase antibody on day 4 posttransfection.
+, complemented; −, not complemented.